In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis.
Ketoconazole, an orally active antimycotic drug, is a potent inhibitor of ergosterol biosynthesis in Candida albicans when added to culture media which support yeast or mycelial growth or to cultures containing outgrown mycelium. This inhibition coincides with accumulation of sterols with a methyl group at C-14 and can thus be attributed to an interference with one of the reactions involved in the removal of the 14 alpha-methyl group of lanosterol. When administered to rats infected with C. albicans, ketocanazole also inhibits fungal synthesis of ergosterol. A six-times-higher dose is required to effect cholesterol synthesis by rat liver.
D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology*; D002176:Candida albicans / Q000187:drug effects / Q000254:growth & development / Q000378:metabolism*; D002462:Cell Membrane / Q000187:drug effects; D002784:Cholesterol / Q000378:metabolism / Q000502:physiology; D003470:Culture Media; D004305:Dose-Response Relationship, Drug; D004875:Ergosterol / Q000096:biosynthesis*; D005260:Female; D007093:Imidazoles / Q000494:pharmacology*; D007654:Ketoconazole; D007810:Lanosterol / Q000378:metabolism / Q000502:physiology; D010879:Piperazines / Q000494:pharmacology*; D051381:Rats; D013261:Sterols / Q000096:biosynthesis / Q000302:isolation & purification; D013997:Time Factors
D000935:Antifungal Agents; D003470:Culture Media; D007093:Imidazoles; D010879:Piperazines; D013261:Sterols; D007810:Lanosterol; D002784:Cholesterol; D007654:Ketoconazole; D004875:Ergosterol